Fond, Guillaume http://orcid.org/0000-0003-3249-2030
Falissard, Bruno
Nuss, Philippe http://orcid.org/0000-0002-3514-4501
Collin, Cedric
Duret, Stephanie
Rabbani, Marc
De Chefdebien, Isabelle
Tonelli, Isabelle
Llorca, Pierre Michel http://orcid.org/0000-0001-7438-8990
Boyer, Laurent http://orcid.org/0000-0003-1229-6622
Funding for this research was provided by:
Lundbeck France Otsuka Pharmaceutical France
Article History
Received: 3 January 2023
Revised: 6 June 2023
Accepted: 19 June 2023
First Online: 21 July 2023
Competing interests
: GF has received honoraria and has been a consultant for Lundbeck. BF has been a consultant for Abbvie, Actelion, Allergan, Almirall, Alnylam, Amgen, Astellas, Astrazeneca, Bayer, Biogen, Biopecs, Bioproject, Biotronik, BMS, Boehringer, Celgene, Daiichi-Sankyo, Ethypharm, Forestlab, Genevrier, Genzyme, Gilead, Grünenthal, GSK, Guerbet, HRA, IDM Pharma, Idorsia, IMS, Indivior, IQVIA, JNJ, Kephren, Lafon, Leo, Lilly, Lundbeck, Menarini, MSD, Novartis, Novonordisk, Otsuka, Pfizer, Pierre-Fabre, Recordati, Roche, Sanofi, Servier, Stallergene, Takeda, UCB, ViiV, and Wellmera. PN has received honoraria and has been an advisor to Lundbeck and Otsuka. CC and SD are employees of IQVIA, a contract research agency responsible for the operational management of the study, funded by Lundbeck. MR and IDC are full-time employees of H. Lundbeck A/S. IT is a full-time employee of Otsuka Pharmaceutical Development & Commercialization Inc. PML has received personal fees from Janssen, Eisai, Ethypharm, Neuraxpharm, Lundbeck, Otsuka and Sanofi, support for meetings from Eisai, Lundbeck and Ethypharm, and fees for advisory boards from Janssen, Eisai, Ethypharm, Lundbeck, MSD, Neuraxpharm, Otsuka, Roche and Sanofi. LB has received honoraria and has been a consultant for Lundbeck.
: This study was submitted to the Institut National des Données de Santé (INDS) in November 2018, which was later replaced by the French Health Data Hub. In January 2019, a favorable opinion was obtained from CEREES (Scientific Committee for Research, Studies and Evaluation in Public Health; later replaced by CESREES [Ethical and Scientific Committee for Research, Studies and Evaluation in Public Health]). The study was approved by the French data protection agency (CNIL) in February 2019 (registration number: 919034; authorization number: DR-2019–065). No informed consent is required for accessing SNDS data.